Latest News & Views in Diabetes Technology

A recent study published in The Lancet reveals that the global prevalence of diabetes is expected to more than double in the next 30 years, affecting over 1.3 billion people worldwide. Currently, over half a billion people are living with diabetes, with a global prevalence rate of 6.1%. Diabetes is identified as one of the top 10 leading causes of death and disability globally. The study highlights regional variations, with the highest rates found in North Africa and the Middle East. Additionally, the research emphasizes that almost all cases (96%) are type 2 diabetes (T2D), with high body mass index (BMI) being the primary risk factor. The study emphasizes the complex nature of diabetes prevention and control, involving genetic, logistical, social, and financial factors. The findings stress the need for a comprehensive understanding of diabetes impact at a granular level to address disparities and improve access to screening and treatment. The study was supported by the Bill & Melinda Gates Foundation.

One educator’s “lessons learned” on working with new technology and upgrades.

The FDA has cleared the iLet Bionic Pancreas system for patients aged 6 and older with type 1 diabetes. The pocket-sized system includes the Beta Bionics iLet ACE pump and the iLet Dosing Decision Software, along with an integrated continuous glucose monitor (CGM). The FDA's decision was based on the system's Breakthrough Device Designation and aims to provide the type 1 diabetes community with more options for diabetes management. The system is easy to initiate, as it only requires the patient's body weight for insulin dosing and does not need manual adjustments. It features a meal announcement feature that estimates carb consumption, removing the need for traditional carb counting. The system demonstrated its efficacy in a pivotal trial, showing improved HbA1c levels and increased time spent in the target glucose range.

American Association of Clinical Endocrinology (AACE) has released the 2023 Comprehensive Type 2 Diabetes Management Algorithm to guide healthcare professionals in clinical decision-making for the management of Type 2 diabetes. The updated algorithm emphasizes a person-centered approach to care, incorporating the latest evidence-based recommendations, associated conditions, complications, and health equity. Key elements include lifestyle modification and treatment of overweight and obesity, treatment of cardiovascular risk factors, and immunization recommendations for people with T2D.

Insulet Corporation has announced the FDA clearance of its latest innovation, Omnipod GO, an insulin delivery device cleared for use for people with type 2 diabetes age 18 or older who would typically take daily injections of long-acting insulin. Omnipod GO is a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The newest addition to the Omnipod brand features a tubeless and waterproof Pod which is offered in seven different pre-programmed daily rates, ranging from 10 to 40 units per day, and operates without the need for a handheld device to control the Pod. The product was developed as an alternative to daily injections. Insulet plans to commercialize Omnipod GO in the United States in 2024.